The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
CAL, Starlux to face penalties for aviation procedural violations
06/15/2025 04:52 PM - Politics
Taiwan's indigenous submarine undergoes final stage of harbor trials
06/15/2025 03:57 PM - Culture
It's a gourd life: Tamsui farmer reclaims 'heaviest pumpkin' title
06/15/2025 03:35 PM - Society
NGOs demand Taiwan provide insurance for domestic migrant workers
06/15/2025 02:54 PM - Society
Temperature in Taipei's Shilin District soars past 37°C on Sunday
06/15/2025 01:32 PM